JP2014527969A - 改変クレアチン化合物 - Google Patents

改変クレアチン化合物 Download PDF

Info

Publication number
JP2014527969A
JP2014527969A JP2014530945A JP2014530945A JP2014527969A JP 2014527969 A JP2014527969 A JP 2014527969A JP 2014530945 A JP2014530945 A JP 2014530945A JP 2014530945 A JP2014530945 A JP 2014530945A JP 2014527969 A JP2014527969 A JP 2014527969A
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
compound
cycloalkyl
creatine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014530945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527969A5 (OSRAM
Inventor
シャハライアー エム． カーン，
シャハライアー エム． カーン，
ロバート シー． ガッドウッド，
ロバート シー． ガッドウッド，
アーサー グレン ロメロ，
アーサー グレン ロメロ，
Original Assignee
ジェンシア コーポレイション
ジェンシア コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェンシア コーポレイション, ジェンシア コーポレイション filed Critical ジェンシア コーポレイション
Publication of JP2014527969A publication Critical patent/JP2014527969A/ja
Publication of JP2014527969A5 publication Critical patent/JP2014527969A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014530945A 2011-09-19 2012-09-18 改変クレアチン化合物 Ceased JP2014527969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161536280P 2011-09-19 2011-09-19
US61/536,280 2011-09-19
PCT/US2012/055887 WO2013043580A2 (en) 2011-09-19 2012-09-18 Modified creatine compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017111480A Division JP2017160254A (ja) 2011-09-19 2017-06-06 改変クレアチン化合物

Publications (2)

Publication Number Publication Date
JP2014527969A true JP2014527969A (ja) 2014-10-23
JP2014527969A5 JP2014527969A5 (OSRAM) 2015-11-12

Family

ID=46982949

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014530945A Ceased JP2014527969A (ja) 2011-09-19 2012-09-18 改変クレアチン化合物
JP2017111480A Pending JP2017160254A (ja) 2011-09-19 2017-06-06 改変クレアチン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017111480A Pending JP2017160254A (ja) 2011-09-19 2017-06-06 改変クレアチン化合物

Country Status (8)

Country Link
US (1) US9434753B2 (OSRAM)
EP (1) EP2758411A2 (OSRAM)
JP (2) JP2014527969A (OSRAM)
CN (1) CN103889993B (OSRAM)
AU (1) AU2012312654B2 (OSRAM)
CA (1) CA2849073A1 (OSRAM)
HK (1) HK1200459A1 (OSRAM)
WO (1) WO2013043580A2 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502911A (ja) * 2014-12-22 2018-02-01 ファーミントン ファーマ ディベロップメントＦａｒｍｉｎｇｔｏｎ Ｐｈａｒｍａ Ｄｅｖｅｌｏｐｍｅｎｔ クレアチンプロドラッグ、その組成物、及びその使用方法
JP2018121621A (ja) * 2017-01-31 2018-08-09 アジレント・テクノロジーズ・インクＡｇｉｌｅｎｔ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 生物フラックスの較正のための方法及び装置
JPWO2019026610A1 (ja) * 2017-08-04 2020-10-29 国立大学法人金沢大学 微小空間の加温方法及び発熱体並びに微小空間の減温方法及び吸熱体

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20121098A1 (it) * 2012-12-18 2014-06-19 Univ Degli Studi Genova Procedimento per sintetizzare derivati della creatina
US9707244B2 (en) 2013-03-15 2017-07-18 Gencia Corporation Compositions and methods for treating conditions that affect epidermis
WO2015069699A1 (en) * 2013-11-05 2015-05-14 Ultragenyx Pharmaceutical Inc. Creatine analogs and the use thereof
AR104144A1 (es) 2015-03-30 2017-06-28 Farmington Pharma Dev Profármacos de análogos de fosfato de creatina, sus composiciones y sus usos
MX2020005707A (es) 2017-12-01 2020-08-20 Ultragenyx Pharmaceutical Inc Profarmacos de creatina, composiciones y metodos de uso de estos.
KR101920902B1 (ko) * 2017-12-27 2018-11-21 전남대학교 산학협력단 심혈관 질환 조기진단 pet 조영용 화합물 및 그의 용도
KR102596981B1 (ko) * 2019-10-30 2023-10-31 주식회사 퓨전바이오텍 미토콘드리아 표적 화합물 및 이를 포함하는 노화 관련 질환의 치료 또는 예방을 위한 조성물
CN115417898B (zh) * 2022-08-02 2024-03-26 浙江工业大学 一种三苯基鏻单体化合物及其制备方法与在制备核酸递送纳米载体中的应用

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014063A1 (en) * 1994-11-08 1996-05-17 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
WO2001000671A1 (en) * 1999-06-25 2001-01-04 Xoma Technology Ltd. Derivative compounds
JP2002510604A (ja) * 1998-04-02 2002-04-09 アビセナ グループ， インク． クレアチン化合物及び第二物質の組み合わせを含む組成
WO2006005759A2 (en) * 2004-07-13 2006-01-19 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
JP2006516652A (ja) * 2003-02-04 2006-07-06 コーネル リサーチ ファウンデイション インコーポレイテッド ミトコンドリア透過性転移の阻止方法
JP2007503387A (ja) * 2003-08-22 2007-02-22 アンティポディーン ファーマシューティカルズ インコーポレイティド ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
US20070066572A1 (en) * 2005-09-14 2007-03-22 Kalyanaraman Balaraman Neuroprotection by positively-charged nitroxides
WO2008039085A1 (en) * 2006-09-28 2008-04-03 University Of Otago Triphenylphosphonium thionitrite nitric oxide donors
WO2010126719A1 (en) * 2009-04-27 2010-11-04 Mcw Research Foundation, Inc. Neuroprotective compounds and their use
JP2010539089A (ja) * 2007-09-07 2010-12-16 ゲンシア コーポレーション ミトコンドリア組成物及びその使用
WO2011011366A2 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
JP2011513231A (ja) * 2008-02-22 2011-04-28 アイアールエム・リミテッド・ライアビリティ・カンパニー ｃ−ｋｉｔおよびＰＤＧＦＲキナーゼ阻害剤としてのヘテロ環化合物および組成物
WO2011082328A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US20060128671A1 (en) 1998-04-02 2006-06-15 The General Hospital Corporation Compositions containing a combination of a creatine compound and a second agent
JP2002523412A (ja) 1998-08-25 2002-07-30 ザ ユーエイビー リサーチ ファウンデイション 細菌ｎａｄシンテターゼ阻害剤
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
DK1147117T3 (da) 1999-02-01 2004-10-25 Eisai Co Ltd Immunologiske adjuvansforbindelser
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6242491B1 (en) 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
MXPA03002649A (es) 2000-09-27 2003-09-25 Ajinomoto Kk Derivado de benzodiazepina.
JP2005298343A (ja) 2002-03-27 2005-10-27 Ajinomoto Co Inc ベンゾジアゼピン誘導体
JP2003321499A (ja) 2002-04-30 2003-11-11 Internatl Reagents Corp ミトコンドリアクレアチンキナーゼ抗体
CA2536546C (en) 2003-08-22 2012-10-02 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
ES2411962T3 (es) 2003-10-24 2013-07-09 Gencia Corporation Métodos y composiciones para suministrar polinucleótidos
US7915230B2 (en) 2005-05-17 2011-03-29 Molecular Transfer, Inc. Reagents for transfection of eukaryotic cells
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
JP5364574B2 (ja) 2006-05-05 2013-12-11 モレキュラー、トランスファー、インコーポレイテッド 真核細胞のトランスフェクションのための新規試薬
CA2734208C (en) 2008-03-14 2018-01-09 Jiri Neuzil Mitochondrially delivered anti-cancer compounds
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
WO2011147199A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014063A1 (en) * 1994-11-08 1996-05-17 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
JP2002510604A (ja) * 1998-04-02 2002-04-09 アビセナ グループ， インク． クレアチン化合物及び第二物質の組み合わせを含む組成
WO2001000671A1 (en) * 1999-06-25 2001-01-04 Xoma Technology Ltd. Derivative compounds
JP2006516652A (ja) * 2003-02-04 2006-07-06 コーネル リサーチ ファウンデイション インコーポレイテッド ミトコンドリア透過性転移の阻止方法
JP2007503387A (ja) * 2003-08-22 2007-02-22 アンティポディーン ファーマシューティカルズ インコーポレイティド ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
WO2006005759A2 (en) * 2004-07-13 2006-01-19 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
US20070066572A1 (en) * 2005-09-14 2007-03-22 Kalyanaraman Balaraman Neuroprotection by positively-charged nitroxides
WO2008039085A1 (en) * 2006-09-28 2008-04-03 University Of Otago Triphenylphosphonium thionitrite nitric oxide donors
JP2010539089A (ja) * 2007-09-07 2010-12-16 ゲンシア コーポレーション ミトコンドリア組成物及びその使用
JP2011513231A (ja) * 2008-02-22 2011-04-28 アイアールエム・リミテッド・ライアビリティ・カンパニー ｃ−ｋｉｔおよびＰＤＧＦＲキナーゼ阻害剤としてのヘテロ環化合物および組成物
WO2010126719A1 (en) * 2009-04-27 2010-11-04 Mcw Research Foundation, Inc. Neuroprotective compounds and their use
WO2011011366A2 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
WO2011082328A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ANALYTICAL CHEMISTRY, vol. 77, no. 17, JPN6016019234, 2005, pages 5662 - 5669, ISSN: 0003324105 *
ANNALS OF THE NEW YORK ACADEMY OF SCIENCE, vol. 1147, JPN6016019244, 2008, pages 395 - 412, ISSN: 0003324108 *
Ｃ．Ｇ．ＷＥＲＭＵＴＨ編, 「最新 創薬化学 下巻」, vol. ３４７〜３６５頁, JPN6014029314, 1999, ISSN: 0003493650 *
ELECTROPHORESIS, vol. 25, JPN6016019227, 2004, pages 1219 - 1229, ISSN: 0003324102 *
GOULD, PHILIP L.: "Salt selection for basic drugs", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 33, JPN6013060611, 1986, pages 201 - 217, ISSN: 0003493649 *
INTERNATIONAL JOURNAL OF MASS SPECTROMETRY, vol. 276, JPN6016019230, 2008, pages 91 - 101, ISSN: 0003324103 *
JOURNAL OF PHYSICAL CHEMISTRY A, vol. 114, no. 25, JPN6016019225, 2010, pages 6888 - 6896, ISSN: 0003324101 *
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 129, no. 40, JPN6016019222, 2007, pages 12232 - 12243, ISSN: 0003324100 *
NATURE STRUCTURAL & MOLECULAR BIOLOGY, vol. 14, no. 8, JPN6016019233, 2007, pages 689 - 695, ISSN: 0003324104 *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 106, no. 26, JPN6017003358, 2009, pages 10764 - 10769, ISSN: 0003493647 *
STEWART, KELLY M.: "Design, Synthesis, and Characterization of a Novel Class of Mitochondrial Delivery Vectors: Mitochon", A THESIS SUBMITTED IN CONFORMITY WITH REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT, JPN6016019241, 23 February 2011 (2011-02-23), ISSN: 0003324107 *
TETRAHEDRON, vol. 65, JPN6017003356, 2009, pages 5284 - 5292, ISSN: 0003493646 *
TEXTBOOK OF DRUG DESIGN AND DISCOVERY, JPN6014038866, 2002, pages 14 - 460, ISSN: 0003493648 *
YOUSIF, LEMA F.: "Mitochondria-penetrating Peptides: Characterization and Cargo Delivery", A THESIS SUBMITTED IN CONFORMITY WITH THE REQUIREMENTS FOR THE DEGREE OF MASTER SCIENCE GRADUATE DEP, JPN6016019237, 17 February 2010 (2010-02-17), ISSN: 0003324106 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502911A (ja) * 2014-12-22 2018-02-01 ファーミントン ファーマ ディベロップメントＦａｒｍｉｎｇｔｏｎ Ｐｈａｒｍａ Ｄｅｖｅｌｏｐｍｅｎｔ クレアチンプロドラッグ、その組成物、及びその使用方法
JP2022078213A (ja) * 2014-12-22 2022-05-24 ファーミントン ファーマ ディベロップメント クレアチンプロドラッグ、その組成物、及びその使用方法
JP7676338B2 (ja) 2014-12-22 2025-05-14 ファーミントン ファーマ ディベロップメント クレアチンプロドラッグ、その組成物、及びその使用方法
JP2018121621A (ja) * 2017-01-31 2018-08-09 アジレント・テクノロジーズ・インクＡｇｉｌｅｎｔ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 生物フラックスの較正のための方法及び装置
JP7025934B2 (ja) 2017-01-31 2022-02-25 アジレント・テクノロジーズ・インク 生物フラックスの較正のための方法及び装置
JPWO2019026610A1 (ja) * 2017-08-04 2020-10-29 国立大学法人金沢大学 微小空間の加温方法及び発熱体並びに微小空間の減温方法及び吸熱体

Also Published As

Publication number Publication date
CN103889993A (zh) 2014-06-25
US9434753B2 (en) 2016-09-06
CA2849073A1 (en) 2013-03-28
HK1200459A1 (en) 2015-08-07
CN103889993B (zh) 2017-05-31
US20150005258A1 (en) 2015-01-01
AU2012312654A1 (en) 2014-04-03
EP2758411A2 (en) 2014-07-30
AU2012312654B2 (en) 2017-04-13
JP2017160254A (ja) 2017-09-14
WO2013043580A3 (en) 2013-06-27
WO2013043580A2 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
JP2017160254A (ja) 改変クレアチン化合物
CN102471248B (zh) 用于递送1,3-丙二磺酸的方法、化合物和组合物
CN101848918A (zh) 线粒体组合物及其用途
IL268721A (en) Cyclic d-nucleotide compounds for the treatment of cancer
EP2066680B1 (en) Triphenylphosphonium thionitrite nitric oxide donors
CN111417620A (zh) 肌酸前药、其组合物以及使用方法
TWI741979B (zh) 磷酸肌酸類似物前藥、其組成物及用途
US20180000846A1 (en) Compositions and Methods for Treating Conditions That Affect Epidermis
WO2017064657A1 (en) Fluorescent anticancer platinum drugs
US20190270698A1 (en) Compounds and methods for the treatment of neurodegenerative diseases
Omran et al. Synthesis and in vitro evaluation of novel pro-drugs for the treatment of nephropathic cystinosis
ES2343880B1 (es) Piridotienotriazinas como compuestos antiangiogenicos.
CN106866695A (zh) 冬凌草甲素衍生物及其制备和应用
Vervynckt Sythesis of carporide Derivatives for Sodium-Proton Exchange Inhibition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170606

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170801

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180801

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20181122